IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER

Area of Science:

• Oncology
• Immunotherapy
• Gynecologic Oncology

Background:

• Cervical cancer (CC) remains a significant global health challenge, particularly in developing nations.
• While early-stage CC is often curable, advanced or recurrent cases have limited treatment options.
• Current standards for advanced CC include platinum doublet chemotherapy plus bevacizumab, with modest efficacy.

Purpose of the Study:

• To review the emerging role of programmed cell death-1/PD ligand-1 (PD-1/PD-L1) inhibitors in cervical cancer treatment.
• To evaluate the clinical benefit of PD-1/PD-L1 inhibitors in recurrent, persistent, or metastatic CC.
• To discuss ongoing clinical trials investigating PD-1/PD-L1 pathway as a therapeutic target in CC.

Main Methods:

• Review of Phase I/II clinical trials (KEYNOTE 028, KEYNOTE 158, CHECKMATE 358).
• Analysis of data on pembrolizumab and nivolumab efficacy in advanced cervical cancer.
• Examination of ongoing research and recruitment phases for PD-1/PD-L1 inhibitors in CC.

Main Results:

• PD-1/PD-L1 inhibitors have demonstrated clinical benefit as second-line treatment in recurrent, persistent, or metastatic CC.
• Pembrolizumab and nivolumab have shown promise in early-phase trials for advanced cervical cancer.
• Evidence suggests the PD-1/PD-L1 pathway is a viable therapeutic target in CC.

Conclusions:

• PD-1/PD-L1 inhibitors represent a novel and potentially groundbreaking therapeutic option for advanced cervical cancer.
• Further clinical trials are crucial to confirm the long-term effectiveness and optimal use of these immunotherapies in CC.
• These inhibitors offer hope for improved outcomes in patients with limited treatment alternatives.